Polish Experience in Peptide Receptor Radionuclide Therapy

摘要: Patients and Methods: During the period from April 2004 to December 2010, 358 patients underwent peptide receptor radionuclide therapy (PRRT) (90Y–DOTATATE, 177Lu–DOTATATE, 90Y/177Lu–DOTATATE) in Poland. Results: The majority of 90Y–DOTATATE (n = 177) with progression-free survival (PFS)/time progression (TTP) 17–44 months overall (OS) 22–34.2 months. Twelve-month follow-up revealed stable disease (SD) 46–60%, regression (RD) 16–35%, (PD) 7–17%, complete remission (CR) 3% patients. In treated 90Y/177Lu–DOTATATE 44), PFS/TTP was 24.2–28.3 OS 49.8–52.8 showed SD 62–70%, RD 15–20%, PD 10–12% treatment well tolerated. No severe adverse events occurred. Grade 3 toxicity [in leucocytes (WBC) thrombocytes (PLT)] seen 6–20% 90Y–DOTATATE. that group, renal grade 5–12% 4 3–8%. tandem or 177Lu–DOTATATE alone, hematological not observed. Conclusions: results indicate PRRT procedures isotopes used is an effective safe option for metastatic inoperable neuroendocrine tumors (NETs). Our suggest provides longer than single-isotope treatment. Hematological rare all Renal observed only group